Cargando…
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)
Paclitaxel‐induced peripheral neuropathy (PIPN) cannot be predicted from clinical parameters and might have a pharmacogenomic basis. Previous studies identified single nucleotide variants (SNV) associated with PIPN. However, only a subset of findings has been confirmed to date in more than one study...
Autores principales: | Boora, Ganesh K., Kanwar, Rahul, Kulkarni, Amit A., Abyzov, Alexej, Sloan, Jeff, Ruddy, Kathryn J., Banck, Michaela S., Loprinzi, Charles L., Beutler, Andreas S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831281/ https://www.ncbi.nlm.nih.gov/pubmed/26763541 http://dx.doi.org/10.1002/cam4.625 |
Ejemplares similares
-
Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study
por: Adjei, Araba A., et al.
Publicado: (2021) -
Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)
por: Major-Elechi, Brittny T., et al.
Publicado: (2018) -
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018) -
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
por: Cheng, H, et al.
Publicado: (2014) -
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)